Screener
West Pharmaceutical Services WST Payments for Repurchase of Common Stock
Payments for Repurchase of Common Stock at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Dividend payments | (31.5) | (30.3) |
| Proceeds from stock-based compensation awards | 12.4 | 6.0 |
| Employee stock purchase plan contributions | 3.9 | 3.6 |
| Shares purchased under share repurchase programs | (454.3) | (134.0) |
| Shares repurchased for employee tax withholdings | (2.5) | (2.5) |
| Net cash used in financing activities | (473.5) | (161.9) |
| Effect of exchange rates on cash | (10.0) | 27.0 |
| Net (decrease) increase in cash and cash equivalents | (355.5) | 25.1 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's payments for repurchase of common stock?
- West Pharmaceutical Services (WST) reported payments for repurchase of common stock of $156.7M in Q2 2026.
- How has West Pharmaceutical Services's payments for repurchase of common stock changed year-over-year?
- West Pharmaceutical Services's payments for repurchase of common stock increased by 31240.0% year-over-year, from $500K to $156.7M.
- What is the long-term trend for West Pharmaceutical Services's payments for repurchase of common stock?
- Over 2 years (2022 to 2024), West Pharmaceutical Services's payments for repurchase of common stock has grown at a 66.3% compound annual growth rate (CAGR), from $202.9M to $560.9M.
Ask your AI about West Pharmaceutical Services's payments for repurchase of common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude